Navigation Links
NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
Date:8/24/2009

EMERYVILLE, Calif., Aug. 24 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, announced today the company has received acceptance to deliver a poster presentation at the 47th Annual Meeting of the Infectious Diseases Society of America October 29 - November 1, 2009 in Philadelphia.

The poster presentation will describe results from a new study of NVC-422, an Aganocide((R)) compound.

Presentation details are as follows:

    Poster Title:     In Vitro Evaluation of Stable Derivatives of the
                      Chlorotaurines on Infected Human Nail Model as Potent
                      Antifungal Agents for the Treatment of Onychomycosis
    Date/Time:        Saturday, Oct 31, 2009, 12:30 PM - 2:00 PM
    Session:          106-Mycology
    Abstract Number:  1056
    Location:         Poster Hall A
    Author:           Bahram E. Memarzadeh, PhD; NovaBay
                      Pharmaceuticals, Emeryville, CA.

"This important study investigates the potential of NVC-422 to penetrate an infected nail and eradicate fungal infection in a human nail model of Onychomycosis, said Dr. Memarzadeh, Senior Director of Pharmaceutical Development, NovaBay Pharmaceuticals. "This is important data to demonstrate the future potential for NVC-422 in a very large market."

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. In preclinical trials, the Aganocide compounds have shown to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, which render most antibiotics ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability and dosing versatility and flexibility.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions. NovaBay has entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www.novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release of NovaBay's expectations regarding NovaBay's Aganocides penetrating infected nails and eradicating fungal infections in a human nail model thereby demonstrate the future potential for NVC-422 to treat Onychomycosis are forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the risk that results obtained in preclinical models may not be obtained in humans, and the risk that Aganocide may not deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. Other risks relating to NovaBay and its Aganocide compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K, under the caption "Risk Factors" in Item 1A of Part I of that report, which was filed with the Securities and Exchange Commission on March 31, 2009. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
2. NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Societys Highest Award
3. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
4. NovaBay announces third quarter 2007 financial results
5. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
6. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
7. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
8. Sound Pharmaceuticals Receives an Office of Naval Research Award for Its Hearing Loss Research and Development
9. Adamas Pharmaceuticals Raises $40 Million in Series D Financing
10. Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: